Literature DB >> 10341359

The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential.

S H Burstein1.   

Abstract

The discovery of carboxylic acid metabolites of the cannabinoids (CBs) dates back more than three decades. Their lack of psychotropic activity was noted early on, and this resulted in a total absence of further research on their possible role in the actions of the CBs. More recent studies have revealed that the acids possess both analgesic and anti-inflammatory properties and may contribute to the actions of the parent drug. A synthetic analog showed similar actions at considerably lower doses. In this review, a brief survey of the extensive literature on metabolism of delta 9-tetrahydrocannabinol to the acids is presented, while more emphasis is given to the recent findings on the biological actions of this class of CBs. A possible mechanism involving effects on eicosanoids for some of these actions is also suggested. Finally, an analogy with a putative metabolite of anandamide, an endogenous CB, is discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10341359     DOI: 10.1016/s0163-7258(98)00069-2

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  21 in total

1.  New directions in supportive care.

Authors:  Steven M Grunberg
Journal:  Support Care Cancer       Date:  2004-12-10       Impact factor: 3.603

Review 2.  The expanding field of cannabimimetic and related lipid mediators.

Authors:  Heather B Bradshaw; J Michael Walker
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 3.  Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials.

Authors:  Summer Burstein
Journal:  AAPS J       Date:  2005-06-29       Impact factor: 4.009

4.  Exogenous anandamide protects rat brain against acute neuronal injury in vivo.

Authors:  M van der Stelt; W B Veldhuis; G W van Haaften; F Fezza; T Bisogno; P R Bar; G A Veldink; J F Vliegenthart; V Di Marzo; K Nicolay
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

Review 5.  Cannabinoid hyperemesis syndrome.

Authors:  Jonathan A Galli; Ronald Andari Sawaya; Frank K Friedenberg
Journal:  Curr Drug Abuse Rev       Date:  2011-12

6.  Potential anti-inflammatory actions of the elmiric (lipoamino) acids.

Authors:  Sumner H Burstein; Jeffrey K Adams; Heather B Bradshaw; Cristian Fraioli; Ronald G Rossetti; Rebecca A Salmonsen; John W Shaw; J Michael Walker; Robert E Zipkin; Robert B Zurier
Journal:  Bioorg Med Chem       Date:  2007-03-13       Impact factor: 3.641

7.  Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity.

Authors:  M van der Stelt; W B Veldhuis; P R Bär; G A Veldink; J F Vliegenthart; K Nicolay
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

Review 8.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  The cannabinoid acids, analogs and endogenous counterparts.

Authors:  Sumner H Burstein
Journal:  Bioorg Med Chem       Date:  2014-04-01       Impact factor: 3.641

10.  Identification of endogenous acyl amino acids based on a targeted lipidomics approach.

Authors:  Bo Tan; David K O'Dell; Y William Yu; M Francesca Monn; H Velocity Hughes; Sumner Burstein; J Michael Walker
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.